PrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men

TitlePrEP Demonstration Project Showed Superior Adherence with Tenofovir Alafenamide/Emtricitabine Compared to Tenofovir Disoproxil Fumarate/Emtricitabine in a Sample of Partnered Sexual Minority Men
Publication TypePublication
Year of Publication2021
AuthorsRobles G, Sauermilch D, Gandhi M, Starks TJ
JournalAIDS Behav
Volume25
Issue4
Pagination1299-1305
Date Published2021 Apr
ISSN1573-3254
KeywordsAdenine, Anti-HIV Agents, Emtricitabine, HIV Infections, Humans, Male, Pre-Exposure Prophylaxis, Sexual and Gender Minorities, Tenofovir, United States
Abstract

<p>Sexual minority men (SMM) remain at high risk of HIV infection in the United States, and for those in relationships, dyadic functioning may contextualize prevention decisions. Pre-exposure prophylaxis (PrEP) for HIV prevention was previously limited to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) until the FDA approved tenofovir alafenamide/FTC (TAF/FTC) for PrEP in 2019. Data regarding substance use, sexual behavior, holding an active PrEP prescription, and type of PrEP regimen (TDF/FTC versus TAF/FTC) were analyzed from a sample of 421 partnered SMM. The majority of the sample on PrEP reported a TDF/FTC prescription as opposed to TAF/FTC. However, SMM reported significantly better adherence to TAF/FTC than TDF/FTC in multivariable models. Novelty of TAF/FTC, treatment fatigue with TDF/FTC, and/or a belief in TAF/FTC's superior efficacy and mitigated side effects may be plausible contributing factors. More studies using objective adherence metrics and surveys are needed.</p>

DOI10.1007/s10461-020-03095-7
Alternate JournalAIDS Behav
PubMed ID33206262
PubMed Central IDPMC7979438
Grant ListUG3AI133674 / / National Institute of Allergy and Infectious Diseases /
R01 AI143340 / AI / NIAID NIH HHS / United States
U19 HD089875 / HD / NICHD NIH HHS / United States
P30 AI027763 / AI / NIAID NIH HHS / United States
R01 DA045613 / DA / NIDA NIH HHS / United States
R01DA045613 / DA / NIDA NIH HHS / United States
R01 DA041262 / DA / NIDA NIH HHS / United States
R01 MH114735 / MH / NIMH NIH HHS / United States
UG3 AI133674 / AI / NIAID NIH HHS / United States
R34 DA043422 / DA / NIDA NIH HHS / United States
R01 AI098472 / AI / NIAID NIH HHS / United States